Open AccessLinagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial
Author(s) -
Nobuya Inagaki,
Wenying Yang,
Hirotaka Watada,
Lig Ji,
Sven Schnaidt,
Egon Pfarr,
Tomoo Okamura,
Odd Erik Johansen,
Jyothis T. George,
Maximilian von Eynatten,
Julio Rosenstock,
Vlado Perkovic,
Christoph Wanner,
Mark E. Cooper,
John H. Alexander,
Issei Komuro,
Masaomi Nangaku
Publication year - 2019
Publication title -
diabetology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.411
H-Index - 17
eISSN - 2190-1686
pISSN - 2190-1678
DOI - 10.1007/s13340-019-00412-x
Subject(s) - linagliptin , medicine , hazard ratio , kidney disease , albuminuria , renal function , clinical endpoint , diabetes mellitus , type 2 diabetes , myocardial infarction , population , creatinine , randomized controlled trial , gastroenterology , endocrinology , confidence interval , environmental health
Linagliptin, a dipeptidyl peptidase-4 inhibitor, demonstrated cardiovascular and renal safety in type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) with albuminuria and/or kidney disease in the multinational CARMELINA ® trial. We investigated the effects of linagliptin in Asian patients in CARMELINA ® .